Bassan Abraham 4

What Happened
Bassan Abraham, a director of Rani Therapeutics Holdings, Inc. (RANI), received a derivative award on 2026-05-28 covering 123,600 shares. The filing reports an acquisition price of $0.00 (a grant/award of a derivative instrument, not a cash purchase). According to the filing footnote, these are options (the footnote refers to "shares subject to the option") that will vest in full on the first anniversary of the grant, subject to continued service, or sooner upon the company's next annual meeting or a Change in Control.

Key Details

• Transaction date: 2026-05-28; Form 4 filed: 2026-06-01 (filing appears timely under Section 16 two-business-day rule).
• Security: Derivative award (option) covering 123,600 shares; reported acquisition price $0.00.
• Vesting: Vests in full on first anniversary of grant subject to continuous service; or earlier upon next annual stockholder meeting or a Change in Control (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No indication this was a sale or a cash exercise—this is a grant of an option-based award.

Context
This is a compensation-related award (option grant) to a director rather than an open-market purchase or sale. Such grants are routinely used to align directors with shareholder interests and do not necessarily signal the director buying or selling stock. Because it’s a derivative award, the economic value to the insider depends on future stock price movement and any exercise or settlement terms not detailed beyond vesting in the footnote.